News and Trends 23 Jun 2023
Sarepta gets approval for first gene therapy for Duchenne muscular dystrophy
Sarepta Therapeutics, Inc. has announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an Adeno-associated virus (AAV)-based gene therapy for the treatment of ambulatory pediatric patients…